Developing a new drug combination to treat triple negative breast cancer
TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
This study is testing a new way to combine two chemotherapy drugs using tiny particles to help treat triple negative breast cancer, aiming to make the treatment more effective for patients facing this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10925319 on NIH RePORTER |
What this research studies
This research aims to create a novel drug combination using nanotechnology to treat triple negative breast cancer (TNBC), a type of breast cancer known for its aggressive nature and poor prognosis. The approach involves co-delivering two chemotherapy drugs, paclitaxel and platinum-based drugs, within the same nanoparticle to enhance their effectiveness against cancer cells. By utilizing high-capacity polymeric micelles, the researchers hope to improve drug delivery and increase the overall antitumor effect. This pre-clinical research is focused on generating data that could lead to more effective treatment options for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may benefit from advanced treatment options.
Not a fit: Patients with other types of breast cancer or those who do not have a diagnosis of breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple negative breast cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with similar approaches using nanotechnology for drug delivery in cancer treatment.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Kabanov, Alexander V — Univ of North Carolina Chapel Hill
- Study coordinator: Kabanov, Alexander V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.